<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Date: 2016-07-11 16:56:16Biotechnology PEGylation Pharmacokinetics Genencor Polyethylene glycol Palo Alto California |
Add to Reading List |
Microsoft Word - RAYMOND J LAND Board Announcementdoc | ORIGINAL ARTICLE Clinical Implications of Molecular PEGylation on Therapeutic Proteins Nandhakumar Sathyamoorthy, Dhanaraju Dasaratha Magharla Department of Pharmaceutics, GIET School of Pharmacy, Rajahmundry, Andhra PrDocID: 1uHNe - View Document |
| Conjugates prepared with aggregate-free proteins - European Patent Office - EPB1 Conjugates prepared with aggregate-free proteins - European Patent Office - EPB1DocID: 1rrGr - View Document |
| Peg-urate oxidase conjugates and use thereof - European Patent Office - EPB1 Peg-urate oxidase conjugates and use thereof - European Patent Office - EPB1DocID: 1rrm1 - View Document |
| Microsoft Word - Savient Press Release ACRdocDocID: 1rrcY - View Document |
| Microsoft Word - Savient Phase 3 Dosing press releasedocDocID: 1ri7E - View Document |